Ab&B Bio-Tech (HKG:2627) has launched its initial public offering in Hong Kong, aiming to raise as much as HK$518 million, according to a Thursday prospectus filing.
The China-based vaccine company is offering up to 33.44 million H-shares at between HK$12.90 and HK$15.50 each.
The offer comprises 3.34 million shares for Hong Kong investors and 30.10 million shares for international buyers.
The issuer expects to determine its offer price on or before Aug. 6 and disclose the allocations on Aug. 7. Trading is scheduled to begin on the Hong Kong bourse on Aug. 8.
Proceeds from the IPO will be used to develop and register core products, including influenza and rabies vaccines, advance clinical trials, upgrade production facilities, and support sales, R&D, and general working capital needs.
The joint sponsors for the deal are CITIC Securities and CMB International Capital. The joint bookrunners include CLSA, CMB International Capital, Livermore Holdings, Funde Securities, Aristo Securities, BOCI Asia, and ICBC International Securities.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。